Has Encorafenib been officially launched in China?

As of2025, canafenib (Encorafenib) has not been officially approved for marketing in mainland China, so patients cannot directly purchase the drug in domestic hospitals and pharmacies. Canafenib is a BRAF inhibitor commonly used to treat malignant melanoma and certain types of colorectal cancer harboring BRAF V600E mutations. Although it has shown good efficacy in clinical treatment, Chinese patients still need to obtain the drug through overseas channels because the approval process has not yet been completed.

At present, Canafenib has been widely used in Europe and the United States and other countries, and the European original research version is commonly seen on the market. The specifications of this drug mainly include 75mg 42 capsules and 75mg 168 capsules. Among them, the price of a box of 75mg 42 tablets is usually more than 10,000 yuan, while the price of a large package of 75mg 168 tablets may be as high as 40,000 yuan. The price fluctuates greatly and is significantly affected by exchange rates, logistics costs and import channels. Therefore, it is recommended to obtain the latest information on the specific drug purchase price through regular overseas drug purchase platforms or consulting professional medical service institutions.

To ease the financial burden on patients, some countries and regions have approved the marketing of generic versions. The more common one is the Lao version of the generic version of canafenib. This version is produced by a compliant pharmaceutical factory. The ingredients of this version are basically the same as the original drug, but the price is more affordable, with each box selling for about 4,000 yuan. Due to its lower price, the Lao version of generic drugs has become a viable option for many patients with heavy financial burdens, especially those who need long-term medication to maintain therapeutic effects.

Generally speaking, canafenib has not yet been officially launched in China and does not yet meet the conditions for medical insurance reimbursement. For patients with drug needs, choosing overseas original drugs or generic drugs has become the main channel. Whether you choose the European version of the original drug or the Lao version of the generic drug, it is recommended to use it under the guidance of a professional doctor. At the same time, pay attention to the authenticity and efficacy monitoring of the drug to ensure the safety and standardization of treatment. If canafenib is launched in China and entered into the medical insurance directory in the future, the financial pressure on patients will be greatly reduced.

Reference materials:https://www.braftovi.com/